Lixisenatide

利司那肽

Report date: 2026/04/15 20:02:38
NME

Base Information

Drug NameLixisenatide
Drug Alias Namelixisenatidum利西拉来lixisenatida利西拉肽利昔那肽 +[11] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[6] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2013/01/31
Country/TerritoryCzechiaBelgiumBulgaria +[61] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofiZealand Pharma A/S
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis GroupeSanofiSanofi-Aventis U.S. Llc
Inactive CompaniesSanofi-Aventis Recherche & DeveloppementSanofi Winthrop Industrie SASanofi (China) Investment Co Ltd
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes Mellitus, Type 1Diabetes MellitusAcute Coronary Syndrome +[5] 

Other Information

ATC CodeA10BJ03
Related LinksWikipediaDrugBankKEGG